These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 7753174)

  • 1. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
    Luo Y; Hurwitz J; Massagué J
    Nature; 1995 May; 375(6527):159-61. PubMed ID: 7753174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
    Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
    Oncogene; 1999 May; 18(21):3290-302. PubMed ID: 10359535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
    Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
    Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
    Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
    Oncogene; 1999 Jul; 18(30):4313-25. PubMed ID: 10439039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
    Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
    Goubin F; Ducommun B
    Oncogene; 1995 Jun; 10(12):2281-7. PubMed ID: 7784076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
    Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
    Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.
    Sekiguchi T; Hunter T
    Oncogene; 1998 Jan; 16(3):369-80. PubMed ID: 9467962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
    Bilodeau JF; Faure R; Piedboeuf B; Mirault ME
    Exp Cell Res; 2000 May; 256(2):347-57. PubMed ID: 10772807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.
    Li Y; Jenkins CW; Nichols MA; Xiong Y
    Oncogene; 1994 Aug; 9(8):2261-8. PubMed ID: 7913544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G; Hunter T; Ruoslahti E
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells.
    Cayrol C; Knibiehler M; Ducommun B
    Oncogene; 1998 Jan; 16(3):311-20. PubMed ID: 9467956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1.
    Peterson SR; Gadbois DM; Bradbury EM; Kraemer PM
    Cancer Res; 1995 Oct; 55(20):4651-7. PubMed ID: 7553644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
    Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
    Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
    Gong J; Ammanamanchi S; Ko TC; Brattain MG
    Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases.
    Medema RH; Klompmaker R; Smits VA; Rijksen G
    Oncogene; 1998 Jan; 16(4):431-41. PubMed ID: 9484832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
    Lu Y; Yamagishi N; Yagi T; Takebe H
    Oncogene; 1998 Feb; 16(6):705-12. PubMed ID: 9488034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition.
    Nakanishi M; Robetorye RS; Pereira-Smith OM; Smith JR
    J Biol Chem; 1995 Jul; 270(29):17060-3. PubMed ID: 7615495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein.
    Funk JO; Waga S; Harry JB; Espling E; Stillman B; Galloway DA
    Genes Dev; 1997 Aug; 11(16):2090-100. PubMed ID: 9284048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.